Overview
Financials
Units: $M (per-share in $, ratios in %)Revenue & profit
Margins
Valuation
Multiples at each fiscal year end (annual) and current (TTM)Valuation history
Segments
Revenue breakdown (annual, $B). Segments depend on each year’s disclosure.By product
By region
Dividends & earnings
Annual dividend per share ($, split-adjusted)
EPS (diluted), last 16 quarters ($)
Company info
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.